West Pharmaceutical Services Inc (WST) stock
WSTNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3031% above fair value
$404.02−10.10 (-2.44%)
Close on Nov 18, 2026Market cap $28.14BP/E 45.3Yield 0.21%
West Pharmaceutical Services operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
West Pharmaceutical Services's operating income for the twelve months ending Sep 30, 2026 was $780.20M, up 32.7% year over year. For fiscal 2025 it was $584.90M, up 2.6% from the year before. Over ten years it grew 16.4% a year on average. The highest annual figure on record is $752.30M in fiscal 2021.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $584.90M | +2.6% |
| FY2024 | Dec 31, 2024 | $569.90M | -15.7% |
| FY2023 | Dec 31, 2023 | $676.00M | -7.9% |
| FY2022 | Dec 31, 2022 | $734.00M | -2.4% |
| FY2021 | Dec 31, 2021 | $752.30M | +84.9% |
| FY2020 | Dec 31, 2020 | $406.90M | +37.2% |
| FY2019 | Dec 31, 2019 | $296.60M | +23.4% |
| FY2018 | Dec 31, 2018 | $240.30M | +6.4% |
| FY2017 | Dec 31, 2017 | $225.80M | +15.7% |
| FY2016 | Dec 31, 2016 | $195.20M | +51.8% |
| FY2015 | Dec 31, 2015 | $128.60M | -29.3% |
| FY2014 | Dec 31, 2014 | $182.00M | +12.1% |
| FY2013 | Dec 31, 2013 | $162.40M | +20.2% |
| FY2012 | Dec 31, 2012 | $135.10M | +23.3% |
| FY2011 | Dec 31, 2011 | $109.60M | +20.8% |
| FY2010 | Dec 31, 2010 | $90.70M | -7.0% |
| FY2009 | Dec 31, 2009 | $97.50M | -21.4% |
| FY2008 | Dec 31, 2008 | $124.10M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $267.40M | +59.5% |
| Q2 FY2026 | Jun 30, 2026 | $179.10M | +16.5% |
| Q1 FY2026 | Mar 31, 2026 | $177.10M | +65.5% |
| Q4 FY2025 | Dec 31, 2025 | $156.60M | -1.9% |
| Q3 FY2025 | Sep 30, 2025 | $167.60M | +3.9% |
| Q2 FY2025 | Jun 30, 2025 | $153.70M | +21.8% |
| Q1 FY2025 | Mar 31, 2025 | $107.00M | -12.9% |
| Q4 FY2024 | Dec 31, 2024 | $159.60M | -0.8% |
| Q3 FY2024 | Sep 30, 2024 | $161.30M | -9.0% |
| Q2 FY2024 | Jun 30, 2024 | $126.20M | -30.8% |
| Q1 FY2024 | Mar 31, 2024 | $122.80M | -20.9% |
| Q4 FY2023 | Dec 31, 2023 | $160.90M | +24.1% |
| Q3 FY2023 | Sep 30, 2023 | $177.30M | -4.8% |
| Q2 FY2023 | Jun 30, 2023 | $182.50M | -20.1% |
| Q1 FY2023 | Mar 31, 2023 | $155.30M | -18.1% |
| Q4 FY2022 | Dec 31, 2022 | $129.70M | -29.5% |
| Q3 FY2022 | Sep 30, 2022 | $186.20M | +2.6% |
| Q2 FY2022 | Jun 30, 2022 | $228.40M | +8.1% |
| Q1 FY2022 | Mar 31, 2022 | $189.70M | +8.0% |
| Q4 FY2021 | Dec 31, 2021 | $184.00M | +58.5% |
| Q3 FY2021 | Sep 30, 2021 | $181.40M | +82.9% |
| Q2 FY2021 | Jun 30, 2021 | $211.30M | +104.0% |
| Q1 FY2021 | Mar 31, 2021 | $175.60M | +99.5% |
| Q4 FY2020 | Dec 31, 2020 | $116.10M | +48.7% |
| Q3 FY2020 | Sep 30, 2020 | $99.20M | +47.4% |
| Q2 FY2020 | Jun 30, 2020 | $103.60M | +28.7% |
| Q1 FY2020 | Mar 31, 2020 | $88.00M | +24.5% |
| Q4 FY2019 | Dec 31, 2019 | $78.10M | +18.7% |
| Q3 FY2019 | Sep 30, 2019 | $67.30M | +10.7% |
| Q2 FY2019 | Jun 30, 2019 | $80.50M | +33.5% |
| Q1 FY2019 | Mar 31, 2019 | $70.70M | +32.4% |
| Q4 FY2018 | Dec 31, 2018 | $65.80M | +8.9% |
| Q3 FY2018 | Sep 30, 2018 | $60.80M | -3.3% |
| Q2 FY2018 | Jun 30, 2018 | $60.30M | +43.6% |
| Q1 FY2018 | Mar 31, 2018 | $53.40M | -11.7% |
| Q4 FY2017 | Dec 31, 2017 | $60.40M | +14.6% |
| Q3 FY2017 | Sep 30, 2017 | $62.90M | – |
| Q2 FY2017 | Jun 30, 2017 | $42.00M | – |
| Q1 FY2017 | Mar 31, 2017 | $60.50M | – |
| Q4 FY2016 | Dec 31, 2016 | $52.70M | – |
See a number that looks wrong?